摘要
目的:观察澳沙利铂联合表阿霉素及5-FU、醛氢叶酸(EOF方案)对晚期胃癌的近期疗效及安全性。方法:入选者为病理证实的晚期胃腺癌患者。化疗方案:表阿霉素50mg/m2静脉注射,d1,澳沙利铂85mg/m2静脉滴注2小时,d1,甲酰四氢叶酸200mg/m2静脉滴注2小时,d1～3,5-FU500mg/m2持续静脉泵入22小时,d1～3,每三周重复,至少完成3个周期判效。结果:共计37例入组,36例可评价疗效及不良反应。其中男28例,女8例,中位年龄52岁(32～75岁),治疗总周期数130周期,平均3.6周期。CR2例(5.6%),PR13例(36.1%),总缓解率RR41.7%,SD47.2%(17/36),PD11.1%(4/36),KPS评分提高20分以上者38.9%(14/36),CBR改善者占50.0%。Ⅲ°/Ⅳ°主要不良反应为中性粒细胞减少19.4%(7/36),血小板减少11.1%(4/36),贫血8.3%(3/36),恶心呕吐8.3%(3/36),腹泻2.8%(1/36),感觉神经异常11.1%(4/36)。结论:本研究显示,此方案治疗晚期胃癌疗效肯定,不良反应能够耐受。
Objective: To evaluate efficacy and toxicity of the regimen of oxaliplatin combined with Epirubicin and 5Fu/LV(EOF) in treatment of patients with advanced gastric cancer. Method: Thirty-seven patients who was pathologically confirmed as advanced gastric cancer received chemotherapy of the regimen: Epirubicin 50mg/m2 Ⅳ 2h d1, Oxaliplatin 85mg/m2 Ⅳ 2h d1, Lecovorin (LV)200mg/m2 Ⅳ 2h d1-3,,5Fu 500mg/m2 Civ 22h d1-3 civ repeated, every 3 weeks for at least 3 cycles. Results: Thirty-seven patients were enrolled, of which 36 were evaluable for efficacy and toxicity. Mean age was 52 years old, 28 cases for men, 8 cases for women. Totally 130 cycles were received, average 3.6 cycles per patient. Among them CR 2 patients, PR 13 patients, the overall response rate (CR+PR) was 41.7%, SD 47.2%, PD 11.1%, KPS improve for 38.9%(14/36), CBR improve for 50.0%. The main toxicity was bone marrow suppression: Ⅲ°/Ⅳ° Neutropenia 19.4%, Thymocytopenia 11.1%, Anemia 8.3%; Ⅲ°/Ⅳ° nausea and vomiting 8.3%, diarrhea 2.8%; Ⅲ° Neuropathy 11.1%. Conclusion: The EOF regimen is effective and tolerable in treatment advanced gastric cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第8期472-475,共4页
Chinese Journal of Clinical Oncology
